- Home
- RILY vs SWKH Comparison
RILY vs SWKH Comparison
Compare RILY & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RILY | SWKH |
|---|---|---|
| Founded | 1973 | 1996 |
| Country | United States | United States |
| Employees | 2056 | 9 |
| Industry | Investment Managers | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.6M | 198.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RILY | SWKH |
|---|---|---|
| Price | $7.46 | $17.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 723.7K | 7.8K |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.99 | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $13.00 |
| 52 Week High | $10.97 | $18.66 |
Technical Indicators
Market Signals| Indicator | RILY | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 59.19 |
| Support Level | $6.15 | $17.16 |
| Resistance Level | $7.94 | $17.71 |
| Average True Range (ATR) | 0.59 | 0.33 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 63.60 | 100.00 |
Price Performance
Historical ComparisonAbout RILY B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.